Search

Danesh, M J, E B Koo, and A B Kimball. 2016. “Effects of TNF-Alpha Antagonism in Patients With Metabolic Syndrome and Psoriasis.”. Journal of the European Academy of Dermatology and Venereology : JEADV 30 (11): e152-e154.

Clowse, Megan E B, Steven R Feldman, John D Isaacs, Alexandra B Kimball, Vibeke Strand, Richard B Warren, Daniel Xibillé, et al. 2016. “Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.”. Drug Safety 39 (8): 755-62.

Strober, Bruce E, Robert Bissonnette, David Fiorentino, Alexa B Kimball, Luigi Naldi, Neil H Shear, Kavitha Goyal, et al. 2016. “Comparative Effectiveness of Biologic Agents for the Treatment of Psoriasis in a Real-World Setting: Results from a Large, Prospective, Observational Study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).”. Journal of the American Academy of Dermatology 74 (5): 851-61.e4.

Kimball, A B, E Edson-Heredia, B Zhu, J Guo, T Maeda-Chubachi, W Shen, and M T Bianchi. 2016. “Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor.”. Journal of Drugs in Dermatology : JDD 15 (2): 183-8.

Blauvelt, Andrew, Alexa B Kimball, Matthias Augustin, Yukari Okubo, Michael M Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, and Bruce Strober. 2022. “Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase III Trial (OASIS-1).”. The British Journal of Dermatology 187 (6): 866-77.

Kumar, Sandeep, Kelsey Flood, Nicole M Golbari, Alexandra P Charrow, Martina L Porter, and Alexa B Kimball. 2021. “Psoriasis: Knowledge, Attitudes and Perceptions Among Primary Care Providers.”. Journal of the American Academy of Dermatology 84 (5): 1421-23.

Golbari, N M, S J Lockwood, M L Porter, and A B Kimball. 2018. “Assessment of Treatment-Seeking Behaviour in Patients With Psoriasis.”. The British Journal of Dermatology 179 (4): 989-90.

Papp, K A, A Blauvelt, A B Kimball, C Han, B Randazzo, Y Wasfi, Y-K Shen, S Li, and C E M Griffiths. 2018. “Patient-Reported Symptoms and Signs of Moderate-to-Severe Psoriasis Treated With Guselkumab or Adalimumab: Results from the Randomized VOYAGE 1 Trial.”. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (9): 1515-22.

Griffiths, Christopher E M, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, and Andrew Blauvelt. 2018. “Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.”. Journal of Drugs in Dermatology : JDD 17 (8): 826-32.

Zachariae, Claus, Kenneth Gordon, Alexandra B Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge, and Gregory Cameron. 2018. “Efficacy and Safety of Ixekizumab over 4 years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis.”. Journal of the American Academy of Dermatology 79 (2): 294-301.e6.